In the TCR-T field, when CXCR2 was transduced into pmel-1 TCR transgenic T cells (173), or MAGE-A3-specific TCR-engineered T cells (174), the CXCR2-TCR-T cells showed increased in vivo homing, enhanced tumor infiltration, and preferential accumulation in tumor sites in mice, with enhanced survival and tumor regression compared with mice receiving control TCR-T cells. The gene discussed is MAGEA3; the disease is neoplasm.